To include your compound in the COVID-19 Resource Center, submit it here.

BBR 2778: Phase II

NOV said preliminary analysis of an open-label European Phase II trial in 33 patients

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE